Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O1UZ
|
||||
| Former ID |
DNC000386
|
||||
| Drug Name |
Cannabidiol
|
||||
| Synonyms |
cannabidiol; 13956-29-1; (-)-Cannabidiol; (-)-trans-Cannabidiol; Epidiolex; UNII-19GBJ60SN5; (-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinol; delta1(2)-trans-Cannabidiol; (-)-CBD; GWP42003-P; CBD; 19GBJ60SN5; QHMBSVQNZZTUGM-ZWKOTPCHSA-N
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Dravet syndrome [ICD-11: 8A61.11] | Approved | [1] | ||
| LennoxGastaut syndrome [ICD-11: 8A62.1] | Approved | [1] | |||
| Company |
GW Pharmaceuticals
|
||||
| Structure |
 |
Download2D MOL |
|||
| Formula |
C21H30O2
|
||||
| Canonical SMILES |
CCCCCC1=CC(=C(C(=C1)O)C2C=C(CCC2C(=C)C)C)O
|
||||
| InChI |
1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
|
||||
| InChIKey |
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
|
||||
| CAS Number |
CAS 145514-04-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
841235, 8707245, 12012585, 14825860, 14899058, 24892861, 43765781, 57309735, 57408178, 57654032, 80649036, 103460177, 104014242, 104152845, 109827355, 113635231, 134990571, 135697550, 136213730, 142472550, 160711726, 162224688, 178100971, 198983043, 224092533, 226491388, 242059005, 250138861, 252159978, 252415453
|
||||
| ChEBI ID |
CHEBI:69478;
|
||||
| SuperDrug ATC ID |
J05AB04
|
||||
| SuperDrug CAS ID |
cas=036791045
|
||||
| Target and Pathway | |||||
| Target(s) | Cannabinoid receptor (CB) | Target Info | Binder | [2] | |
| References | |||||
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | ||||
| REF 2 | (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.